Association Between High-Sensitivity C-Reactive Protein and Prognosis of Patients with Acute Cerebral Infarction
DOI: https://doi.org/10.2147/NDT.S376440
IF: 2.989
2022-08-20
Neuropsychiatric Disease and Treatment
Abstract:Yuting Pu, 1, 2 Shuangyang Li, 2 Lingxue Wang, 2 Bangjiang Fang, 1 Xue Bai 2 1 LongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, People's Republic of China; 2 Department of Neurology and National Traditional Chinese Medicine Clinical Research Base, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China Correspondence: Xue Bai, Department of Neurology and National Traditional Chinese Medicine Clinical Research Base, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China, Email Purpose: To investigate the association of serum high-sensitivity C-reactive protein (hs-CRP) with the severity of neurological deficits and prognosis in patients with acute cerebral infarction (ACI). Patients and Methods: In this retrospective analysis, 119 patients with ACI were recruited from January to December 2020. The serum hs-CRP level was measured by a latex-enhanced immunoturbidimetric assay. The severity of neurological deficits and prognosis of ACI patients were assessed using the National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS). Multivariate logistic analysis was performed and receiver operating characteristic (ROC) curves were plotted to evaluate the value of hs-CRP in predicting the prognosis of ACI. Results: The patients with a more favorable prognosis (mRS score 0– 2) had a lower median serum hs-CRP level than those with a worse prognosis (mRS score 3– 6) (3.32 IQR: 1.51, 8.04 to 17.93 IQR:16.02, 19.01; P< 0.001). After adjusting for potential confounders, multivariable linear regression showed that serum hs-CRP level was independently associated with NIHSS score (Beta = 0.952, P< 0.001) and mRS score (Beta=0.878, P< 0.001). Multivariate logistic analysis revealed that high hs-CRP level was an independent predictor of the poor prognosis in patients with ACI (adjusted 1 OR = 1.995; 95% CI = 1.499– 2.655; adjusted 2 OR = 2.75; 95% CI = 1.015– 7.457). ROC curve analysis indicated that the area under the curve for hs-CRP to predict poor prognosis was 0.986. The cutoff value, sensitivity, and specificity were 11.835 mg/L, 95%, and 92.5%, respectively. In terms of ischemic stroke subtypes, the serum hs-CRP level was higher in large-artery atherosclerosis (LAA) patients than in those with small-artery occlusion (SAO) and cardioembolism (CE). In addition, the patients with LAA had higher scores of NIHSS and mRS than those with SAO and CE. Conclusion: Serum hs-CRP level is an independent predictor of prognosis, and an efficient index to discriminate patients with ACI, especially for those with LAA. Keywords: acute cerebral infarction, high-sensitivity C-reactive protein, neurological deficits Stroke is the second leading cause of death and the third leading cause of disability in patients with cerebrovascular diseases worldwide. 1 Acute cerebral infarction (ACI) accounts for 69.6–70.8% of all stroke cases. The high morbidity, disability, and mortality due to ACI pose a heavy burden on public health. 2 Early prediction of ACI risk and prognosis is essential to the successful management of ACI. ACI manifests brain tissue necrosis caused by ischemia and hypoxia. 3 Cerebral atherosclerosis is the most common cause of ACI. 4,5 Inflammation affects cerebral atherosclerosis and plays a critical role in the pathogenesis of ACI. 6–8 High-sensitivity c-reactive protein (hs-CRP) is a marker of acute nonspecific inflammation in the course of ACI. 9 Previous studies have revealed that a high hs-CRP level predicts a poor prognosis for ACI patients. 10 However, the association between hs-CRP and the degree of neurological deficits and prognosis is unclear in different stroke subtypes. This study aimed to investigate the hs-CRP level in different ischemic stroke subtypes and their associations with the scores measured with the National Institutes of Health Stroke Scale (NIHSS) and the 3-month modified Rankin Scale (mRS). A total of 119 patients diagnosed with ACI and hospitalized from January 2020 to December 2020 in the Department of Neurology of the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University were enrolled. Included were those aged >18 years, with symptoms setting on within 72 hours and confirmed by imaging data (CT or MRI). The Trial of Org 10,172 in Acute Stroke Treatment (TOAST) is a system for classification of subtypes of ischemic stroke based on etiology, including large-artery atherosclerosis (LAA), card -Abstract Truncated-
psychiatry,clinical neurology